Healthcare
Live Price
Offline$12.01
-1.56% today
1Y Change
-63.37%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tonix Pharmaceuticals Holding Corp. (TNXP) is a Healthcare stock with a market cap of $190.00M and listed on NASDAQ. The stock last traded around $12.01 and down 63.4% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +29.8%, EPS growth of +91.7%, a dividend yield of 0.0%. What stands out right now is revenue +29.8%, EPS +91.7%, free cash flow -69.1% with operating margin -959.1% and ROIC -51.0%. Valuation already assumes a fairly strong business story at price/sales 14.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TNXP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNXP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TNXP Max Drawdown
-82.70%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TNXP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$92.3M
+16.3% YoY
Free Cash Flow
-$110.9M
+24.2% YoY
Revenue Growth
+29.8%
EPS Growth
+91.7%
Gross Margin
49.3%
Net Margin
-946.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 13M | 10M | 8M | 0 | 0 |
| Gross Profit | 6M | 2M | 3M | 0 | 0 |
| Operating Income | -126M | -137M | -118M | -112M | -92M |
| EBITDA | -124M | -74M | -114M | -111M | -92M |
| Net Income | -124M | -130M | -117M | -110M | -92M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 208M | 99M | 25M | 120M | 179M |
| Total Assets | 277M | 163M | 154M | 226M | 241M |
| Total Liabilities | 32M | 23M | 49M | 19M | 22M |
| Shareholder Equity | 245M | 140M | 106M | 207M | 219M |
| Total Debt | 1M | 5M | 10M | 760K | 956K |
| Net Debt | -206M | -93M | -15M | -119M | -178M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
76M
+22.9% YoY
Capital Expenditures
35M
+26.7% YoY
Free Cash Flow
111M
+24.2% YoY
Key ratios
Gross Margin
49.3%
Operating Margin
-959.1%
Net Margin
-946.2%
ROE
-60.2%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.